Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 40

Warning: Undefined variable $count in /home/seniorca/public_html/wp-content/themes/divi-news-child-healthcare/index.php on line 121

Stat of the Week: December 2017 +23%

Talk about saving the best for last. For months, deal volume has stagnated, slipped, and failed to excite. Then December happened. Six deals with prices over $1 billion were announced, and their combined value was $91.7 billion. Of course, the CVS/Aetna (NYSE: CVS/AET) deal accunted for most of that, at $77 billion. But what counts is that these deals showed the game is changing in the healthcare market, and market forces and investors are working outside the usual Medicare/Medicaid reimbursement policies. Let’s start with December’s deal volume. At 121 transactions (so far, more will undoubtedly be added), the total is up 23% compared with November’s 98 transactions, but 5% lower than the... Read More »
Q4:17 Redefined Healthcare M&A

Q4:17 Redefined Healthcare M&A

Despite all the big deals announced in December, the fourth quarter of 2017 wasn’t one for the record books. Merger and acquisition activity was busy, but compared with the previous quarter and the same period in 2016, the pace wasn’t frenetic. Our preliminary data shows 357 transactions were announced in Q4:17, down a slight 4% compared with the third quarter of 2017, and down 8% versus the fourth quarter of 2016. Dollar volume, on the other hand, was quite high. Preliminary data (again) shows nearly $114.3 billion was spent in Q4:17, a 165% gain over Q3:17, and nearly 200% over Q4:16. That total rests largely on the back of a single deal, which you’ve probably heard... Read More »
Top 10 Health Care Deals of 2017

Top 10 Health Care Deals of 2017

“Variety” best describes the top 10 healthcare deals announced in 2017. The target companies spanned sectors from Biotechnology and Medical Devices to Managed Care and Other Services. You know the healthcare game is changing when just a single pharmaceutical target made the list in 2017, compared with six of the top 10 deals in 2015. The 10 largest deals total $182.1 billion, and account for 59% of the year’s preliminary deal value total of approximately $310.7 billion. In 2016, the top-10 accounted for 51% of the year’s $256.7 billion in spending. In 2017, a Managed Care target was again the largest target of the year. Unlike in 2o15, when the Big Five managed care companies... Read More »

Health Care M&A Weekly Deals, The Week Ending January 5, 2018

We hope you are enjoying your membership to HealthCareMandA.com. This Health Care M&A Weekly chart below is a selection of transactions announced during the prior week(s). The deals presented here are further elaborated in the monthly newsletter, Health Care M&A News, and in the quarterly report. This information also appears in our online database, Deal Search Online. Visit www.dealsearchonline.com to open a guest account and begin your search. Biotechnology     Acquirer Target Price Pfizer Inc. Collaboration on PROTACs N/A Roche Research collaboration on novel bispecific molecule $10 million Biocrates Life Sciences AG Metanomics Health GmbH N/A Reckitt... Read More »

Health Care M&A Weekly Deals, The Week Ending December 15, 2017

We hope you are enjoying your membership to HealthCareMandA.com. This Health Care M&A Weekly chart below is a selection of transactions announced during the prior week(s). The deals presented here are further elaborated in the monthly newsletter, Health Care M&A News, and in the quarterly report. This information also appears in our online database, Deal Search Online. Visit www.dealsearchonline.com to open a guest account and begin your search. Behavioral Health Care     Acquirer Target Price       Biotechnology     Acquirer Target Price Allergan plc Repros Therapeutics Inc. $26.5 million Ono Pharmaceutical Co., Ltd.... Read More »
Top 10 Health Care Deals of 2017

Stat of the Week: November Deal Volume -30%

Perhaps it was the anticipation of the Thanksgiving holiday, or the holiday itself, that caused the sudden slump in deal volume. Too much turkey, too little focus on finishing up those transactions? Or we could blame the Republicans’ mad dash to pass their tax “reform” legislation before the end of the year. Both houses of Congress have passed separate versions of the bill, and are presently reconciling those into one, for a final vote. How that will look at the other end of the sausage machine is anyone’s guess, but once the bill is passed, we may see the floodgates open on pent-up demand in the more global sectors, such as Medical Devices and Pharmaceuticals. This is preliminary data, of... Read More »